Baclofen add-on to citalopram in treatment of posttraumatic stress disorder

Journal of Clinical Psychopharmacology

Volumn 34, Issue 2, 2014, Pages 240-243

  Manteghi, Ali Akhoundpour ^a   Hebrani, Paria ^a   Mortezania, Mohammad ^a   Haghighi, Mehri Baghban ^a   Javanbakht, Arash ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Baclofen; Citalopram; GABA; PTSD; SSRI

Indexed keywords

BACLOFEN; CITALOPRAM; PLACEBO;

ADD ON THERAPY; ADULT; ANXIETY; AROUSAL; ARTICLE; AVOIDANCE BEHAVIOR; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; GLOBAL ASSESSMENT OF FUNCTIONING; HAMILTON SCALE; HUMAN; IRAN; MIDDLE AGED; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VETERAN;

ADULT; AGED; BACLOFEN; CITALOPRAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GABA-B RECEPTOR AGONISTS; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; VETERANS;

EID: 84896401953     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000089     Document Type: Article

References (39)

1. Albucher RC, Liberzon I. Psychopharmacological treatment in PTSD: a critical review. J Psychiatr Res. 2002;36(6): 355-367.
2. Asnis GM, Kohn SR, Henderson M, et al. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs. 2004;64(4): 383-404.
3. Davidson JR. Long-term treatment and prevention of posttraumatic stress disorder. J Clin Psychiatry. 2004;65: 44-48.
4. Sadock BJ, Sadock VA. Kaplan & Sadock's Synopsis of Psychiatry: Anxiety Disorders. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 579-627.
5. Broekman BF, Olff M, Boer F. The genetic background to PTSD. Neurosci Biobehav Rev. 2007;31(3): 348-362.
6. Van Ameringen M, Mancini C, Pipe B, et al. Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs. 2004;64(19): 2199-2220.
7. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;13(3): 141-146.
8. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159(10): 1777-1779.
9. Berlin HA. Antiepileptic drugs for the treatment of post-traumatic stress disorder. Curr Psychiatry Rep. 2007;9(4): 291-300.
10. Bastien DL. Pharmacological treatment of combat-induced PTSD: a literature review. Br J Nurs. 2010;19(5): 318-321.
11. Robert S, Hamner MB, Durkalski VL, et al. An open-label assessment of aripiprazole in the treatment of PTSD. Psychopharmacol Bull. 2009;42(1): 69-80.
12. Malek-Ahmadi P. Gabapentin and posttraumatic stress disorder. Ann Pharmacother. 2003;37(5): 664-666.
13. Adamou M, Puchalska S, Plummer W, et al. Valproate in the treatment of PTSD: systematic review and meta analysis. Curr Med Res Opin. 2007;23(6): 1285-1291.
14. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2): 371-373.
15. Nikolaus S, Antke C, Beu M, et al. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disordersVresults from in vivo imaging studies. Rev Neurosci. 2010;21(2): 119-139.
16. Birmes P, Senard JM, Escande M, et al. Biological factors of PTSD: neurotransmitters and neuromodulators. Encephale. 2002; 28(3 Pt 1): 241-247.
17. Geuze E, van Berckel BN, Lammertsma AA, et al. Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder. Mol Psychiatry. 2008;13(1): 74-83.
18. Spivak B, Maayan R, Kotler M, et al. Elevated circulatory level of GABA(A)Yantagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psychol Med. 2000;30(5): 1227-1231.
19. Feusner J, Ritchie T, Lawford B, et al. GABA(A) receptor beta 3 subunit gene and psychiatric morbidity in a post-traumatic stress disorder population. Psychiatry Res. 2001;104(2): 109-117.
20. Vaiva G, Thomas P, Ducrocq F, et al. Low posttrauma GABA plasma levels as a predictive factor in the development of acute posttraumatic stress disorder. Biol Psychiatry. 2004;55(3): 250-254.
21. Vaiva G, Boss V, Ducrocq F, et al. Relationship between posttrauma GABA plasma levels and PTSD at 1-year follow-up. Am J Psychiatry. 2006;163(8): 1446-1448.
22. Pae CU, Marks DM, Han C, et al. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. Int Clin Psychopharmacol. 2009;24(1): 29-33.
23. Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry. 2003;64(12): 1421-1425.
24. Connor KM, Davidson JR, Weisler RH, et al. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl). 2006;184(1): 21-25.
25. Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007;27(1): 85-88.
26. Pollack MH, Hoge EA, Worthington JJ, et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(7): 892-897.
27. Addolorato G, Leggio L, Cardone S, et al. Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol. 2009;43(7): 559-563.
28. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des. 2010;16(19): 2113-2117.
29. Drake RG, Davis LL, Cates ME, et al. Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother. 2003;37: 1177-1181.
30. Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8: 75-90.
31. Jones SH, Thornicroft G, Coffey M, et al. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. 1995;166(5): 654-659.
32. Hamilton MC. Hamilton anxiety scale. HAMA. 1959.
33. Javanbakht A, Liberzon I, Amirsadri A, et al. Event-related potential studies of post-traumatic stress disorder: a critical review and synthesis. Biol Mood Anxiety Disord. 2011;1(1): 5.
34. Garfinkel SN, Liberzon I. Neurobiology of PTSD: a review of neuroimaging findings. Psychiatric Annals. 2009; 39(6): 370-372.
35. Suvak MK, Barrett LF. Considering PTSD from the perspective of brain processes: a psychological construction approach. J Trauma Stress. 2011;24(1): 3-24.
36. Dadi(-Hero E, Tori( I, Ruzi( K, et al. ComorbidityVa troublesome factor in PTSD treatment. Psychiatr Danub. 2009;21(3): 420-424.
37. Ikin JF, Creamer MC, Sim MR, et al. Comorbidity of PTSD and depression in Korean War veterans: prevalence, predictors, and impairment. J Affect Disord. 2010;125(1-3): 279-286.
38. Garieballa SS, Schauer M, Neuner F, et al. Traumatic events, PTSD, and psychiatric comorbidity in forensic patientsVassessed by questionnaires and diagnostic interview. Clin Pract Epidemiol Ment Health. 2006;2: 7.
39. Momartin S, Silove D, Manicavasagar V, et al. Comorbidity of PTSD and depression: associations with trauma exposure, symptom severity and functional impairment in Bosnian refugees resettled in Australia. J Affect Disord. 2004;80(2-3): 231-238.